CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials

Reuters

Sep 30

CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials

CollPlant Biotechnologies Ltd. has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, based on its proprietary non-animal recombinant human collagen (rhCollagen) technology. The comprehensive research program demonstrated long-term durability, biocompatibility, and compliance with international standards, establishing a strong foundation for clinical advancement. These results have not yet been presented publicly but support CollPlant's plans to advance the product candidate into clinical trials. The novel filler combines hyaluronic acid and rhCollagen, offering immediate contouring, structural support, and tissue regeneration in a single treatment, and is expected to set a new standard in aesthetic medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO86840) on September 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571349457"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571349457\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571349457?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571349457","market":"us","top_or_hot":-1,"title":"CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CollPlant Biotechnologies Ltd. has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, based on its proprietary non-animal recombinant human collagen (rhCollagen) technology. The comprehensive research program demonstrated long-term durability, biocompatibility, and compliance with international standards, establishing a strong foundation for clinical advancement. These results have not yet been presented publicly but support CollPlant's plans to advance the product candidate into clinical trials. The novel filler combines hyaluronic acid and rhCollagen, offering immediate contouring, structural support, and tissue regeneration in a single treatment, and is expected to set a new standard in aesthetic medicine.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CLGN\">Collplant Biotechnologies</a> Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO86840) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CollPlant Biotechnologies Ltd. has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, based on its proprietary non-animal recombinant human collagen (rhCollagen) technology. The comprehensive research program demonstrated long-term durability, biocompatibility, and compliance with international standards, establishing a strong foundation for clinical advancement. These results have not yet been presented publicly but support CollPlant's plans to advance the product candidate into clinical trials. The novel filler combines hyaluronic acid and rhCollagen, offering immediate contouring, structural support, and tissue regeneration in a single treatment, and is expected to set a new standard in aesthetic medicine.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CLGN\">Collplant Biotechnologies</a> Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO86840) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL7PjKGv:1","article_id":"2571349457","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571349457","pubTimestamp":1759230049,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials. CollPlant Biotechnologies Ltd. has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, based on its proprietary non-animal recombinant human collagen  technology. The comprehensive research program demonstrated long-term durability, biocompatibility, and compliance with international standards, establishing a strong foundation for clinical advancement. These results have not yet been presented publicly but support CollPlant's plans to advance the product candidate into clinical trials. The novel filler combines hyaluronic acid and rhCollagen, offering immediate contouring, structural support, and tissue regeneration in a single treatment, and is expected to set a new standard in aesthetic medicine.Disclaimer: This news brief was created by Public Technologies  using generative","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLGN":"COLLPLANT BIOTECHNOLOGIES LTD"},"translate_title":"CollPlant Biotechnologies宣布新型光固化再生真皮填充物临床前结果积极，为临床试验铺平道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLGN":0.9},"content_text":"CollPlant Biotechnologies Announces Positive Preclinical Results for Novel Photocurable Regenerative Dermal Filler, Paving Way for Clinical Trials\n    \n\n        CollPlant Biotechnologies Ltd. has announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, based on its proprietary non-animal recombinant human collagen (rhCollagen) technology. The comprehensive research program demonstrated long-term durability, biocompatibility, and compliance with international standards, establishing a strong foundation for clinical advancement. These results have not yet been presented publicly but support CollPlant's plans to advance the product candidate into clinical trials. The novel filler combines hyaluronic acid and rhCollagen, offering immediate contouring, structural support, and tissue regeneration in a single treatment, and is expected to set a new standard in aesthetic medicine.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO86840) on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}